I can see AU funding in reach for CHM:
'Hidden killer' set to become Australia's most deadly cancer
By Josh Hohne - 2 days ago
Blood cancer is set to become Australia's most common and deadly cancer with the number of cases expected to double within a decade.
It remains one of the only cancers you can't screen or prevent, so there are urgent calls for more critical research to be done.
[...]
"For every 12 people you know, one of them is going to be unlucky and get a blood cancer," she said.
The percentage share of research in prevention, early detection and diagnosis lacks behind many other cancers.
For cervical cancer it's 90 per cent, melanoma 55 per cent, followed by lung, prostate, bowel and breast cancers. While blood cancer is drastically behind at just 12 per cent.
https://www.9news.com.au/national/b...y-cancer/0d4622b5-1134-4b4a-b40e-61ab8821496c
Australia’s losing the blood cancer fight… urgent action needed to save lives
Friday January 31, 2025
The Leukaemia Foundation is today calling for urgent action revealing blood cancer is set to become Australia’s most common and deadly cancer within a decade unless we act now.
https://www.leukaemia.org.au/media/australias-losing-the-blood-cancer-fight-urgent-action-needed-to-save-lives/#refs
Referenced:
https://www.leukaemia.org.au/wp-con...ust-AAS-Research-Roadmap-for-Blood-Cancer.pdf
RESEARCH ROADMAP FOR BLOOD CANCER
10-YEAR RESEARCH ROADMAP TO ACCELERATE BLOOD CANCER RESEARCH IN AUSTRALIA
OCTOBER 2024
THE QUEST: ZERO PREVENTABLE DEATHS BY 2035
We propose a national quest, supported by government, industry and philanthropic stakeholders, to fast-track research efforts, leverage existing infrastructure and strengths, and build new opportunities and capacity. The quest will address the overarching issues applicable to all healthcare and cancer research and is a shared responsibility of all health researchers to emphasise areas where we can make the greatest differences.
This national quest has the following three priorities:
• Investment in research: Increasing funding for blood cancer research—including fundamental research—with dedicated funding streams to tackle areas of particular need, including difficult-to-target and high-mortality cancers.
• Translation of research into practice: Improving national coordination of research,incentivising multidisciplinary teamwork, enabling strategic international collaboration andpartnerships, and supporting large-scale clinical trials.
• Build the research workforce: Bridging the gap between research and clinical care byempowering researchers and clinician–researchers with the skills, resources, and supportthey need to conduct research, advance health and medical knowledge, and improvepatient care and outcomes.
THREE BLOOD CANCER MISSIONS
To support the quest for zero preventable deaths by 2035 and deliver this Research Roadmap, three missions have been identified that address areas of high unmet need. Each mission offers a new focus for blood cancer research. The Australian Government must lead the investment of $125 million into blood cancer research, spread across the three national missions (see p14).
1. Blood cancers with poor outcomes: We need to explore better options to manage cancers such as acute myeloid leukaemia (AML), poor prognosis multiple myeloma, recurrent aggressivelymphomas, and currently intractable rare blood cancers.
2. Causality and potential for prevention and early detection: This mission should focus on including early detection in populations and the small subset of individuals known to be of high risk of developing a blood cancer from environmental influences, prior cancer therapy, and heritablefactors.
3. Personalised medicine: integrating advanced genomics, and targeted and cellular therapies inmodels of care, aiming to change the natural history of blood cancers.
AML?
"Of significant note, one Acute Myeloid Leukemia patient in the Phase 1A clinical trial achieved a Complete Response (CR) to CHM 0201 and has remained in ongoing complete remission for more than two years to date."
https://company-announcements.copyright link/asx/chm/82febd77-872d-11ee-b257-3a23d711c0da.pdf
"Chimeric COO Dr Rebecca McQualter said: “As the study continues to enrol subjects with advanced cancer, we are pleased to see the clinical combination can be delivered safely, and we are very happy to report that one study subject with advanced Acute Myelogenous Leukemia (AML) experienced a Complete Response at Day 28 after starting treatment with the CHM CORE-NK + Vactosertib combination.” The patient will continue on study and be monitored for up to 15 years, a standard FDA requirement for all cell therapy trials. 3 patients are currently enrolled in the Phase 1b study with the goal to enrol 12 patients."
https://www.listcorp.com/asx/chm/chimeric-therapeutics-limited/news/aml-patient-achieves-complete-response-in-chm-core-nk-trial-3096206.html
This might now be CHM's biggest opportunity to bring CORE-NK to AU and ask for non-dilutive funding!
